LRMR
Larimar Therapeutics Inc.
$3.62
-$0.29(-7.42%)
41
Overall
--
Value
54
Tech
28
Quality
Market Cap
$331.23M
Volume
1.40M
52W Range
$1.61 - $9.50
Target Price
$19.50
Order:
Income Statement
| Metric | Trend | Chart | 2019 Dec | 2020 Dec | 2021 Dec | 2022 Dec | 2023 Dec | 2024 Dec |
|---|---|---|---|---|---|---|---|---|
| REVENUE | ||||||||
| Total Revenue | $112.0K | -- | -- | -- | -- | -- | ||
| GROSS PROFIT | ||||||||
| Gross Profit | $112.0K | -- | -- | -- | -- | -- | ||
| OPERATING EXPENSES | ||||||||
| Operating Expenses | $-23.2M | $42.8M | $50.5M | $36.5M | $41.8M | $90.9M | ||
| Research & Development | $20.8M | $31.4M | $38.4M | $24.3M | $27.7M | $73.3M | ||
| Research Expense | $20.8M | $31.4M | $38.4M | $24.3M | $27.7M | $73.3M | ||
| Selling, General & Administrative | $2.4M | $11.4M | $12.1M | $12.3M | $14.1M | $17.6M | ||
| General & Administrative Expenses | $2.4M | $11.4M | $12.1M | $12.3M | $14.1M | $17.6M | ||
| Salaries & Wages | $-129.0K | -- | -- | -- | $7.6M | $8.8M | ||
| Depreciation & Amortization | $-78.0K | $155.0K | -- | -- | -- | -- | ||
| Depreciation & Amortization | $-78.0K | $155.0K | -- | -- | -- | -- | ||
| Other Operating Expenses | $-45.7M | $700.0K | $300.0K | $300.0K | $41.8M | $90.9M | ||
| OPERATING INCOME | ||||||||
| Operating income | $-23.2M | $-42.8M | $-50.5M | $-36.5M | $-41.8M | $-90.9M | ||
| EBITDA | $-23.1M | $-42.6M | $-50.1M | $-36.2M | $-36.6M | $-80.3M | ||
| NON-OPERATING ITEMS | ||||||||
| Interest Expense (Non-Operating) | $1.8M | -- | -- | -- | -- | -- | ||
| Intinc | $82.0K | -- | -- | -- | -- | -- | ||
| Net Non-Operating Interest Income/Expense | $82.0K | -- | -- | -- | -- | -- | ||
| Other Income/Expense | $-100.0K | $-322.0K | $171.0K | $1.2M | $-4.8M | $-10.3M | ||
| Other Special Charges | -- | $322.0K | $-171.0K | $1.2M | $4.8M | $10.3M | ||
| SPECIAL ITEMS | ||||||||
| Restructring And Mn A Income | $5.6M | -- | -- | -- | -- | -- | ||
| Special Income Charges | $-5.6M | -- | -- | -- | -- | -- | ||
| Other Impairment Of Capital Assets | $-100.0K | -- | -- | -- | -- | -- | ||
| PRE-TAX INCOME | ||||||||
| EBIT | $-23.1M | $-42.8M | $-50.5M | $-36.5M | $-36.9M | $-80.6M | ||
| Pre-Tax Income | $-23.1M | $-42.5M | $-50.6M | $-35.4M | $-36.9M | $-80.6M | ||
| NET INCOME | ||||||||
| Net Income | $-23.1M | $-42.5M | $-50.6M | $-35.4M | $-36.9M | $-80.6M | ||
| Net Income (Continuing Operations) | $-23.1M | $-42.5M | $-50.6M | $-35.4M | $-36.9M | $-80.6M | ||
| Net Income (Discontinued Operations) | $-23.1M | $-42.5M | $-50.6M | $-35.4M | $-36.9M | $-80.6M | ||
| Net Income (Common Stockholders) | $-23.1M | $-42.5M | $-50.6M | $-35.4M | $-36.9M | $-80.6M | ||
| Normalized Income | -- | -- | $-40.0M | -- | -- | -- | ||
| TOTALS | ||||||||
| Total Expenses | $-23.2M | $42.8M | $50.5M | $36.5M | $41.8M | $90.9M | ||
| SHARE & EPS DATA | ||||||||
| Average Shares Outstanding | $3.1M | $11.9M | $17.2M | $25.8M | $43.9M | $61.3M | ||
| Average Shares Outstanding (Diluted) | $3.1M | $11.9M | $17.2M | $25.8M | $43.9M | $61.3M | ||
| Shares Outstanding | $3.1M | $15.4M | $17.7M | $43.3M | $63.8M | $64.0M | ||
| Basic EPS | -- | $-3.57 | $-2.95 | $-1.37 | $-0.84 | $-1.32 | ||
| Basic EPS (Continuing Operations) | -- | $-3.57 | $-2.95 | $-1.37 | $-0.84 | $-1.32 | ||
| Diluted EPS | $-14.64 | $-3.57 | $-2.95 | $-1.37 | $-0.84 | $-1.32 | ||
| Diluted EPS (Continuing Operations) | -- | -- | $-2.95 | $-1.37 | $-0.84 | $-1.32 | ||
| OTHER METRICS | ||||||||
| Other Gand A | $2.4M | $11.4M | $12.1M | $12.3M | $14.1M | $17.6M | ||
| Rent And Landing Fees | $2.4M | -- | -- | -- | -- | -- | ||
| Restruct | $5.6M | -- | -- | -- | -- | -- | ||
Financial data is updated quarterly and may not reflect the most recent earnings.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | LRMR | $3.62 | -7.4% | 1.40M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Larimar Therapeutics Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW